Recombinant adeno-associated viruses (rAAVs) containing a corrective gene of interest are excellent nucleic acid delivery vehicles for gene therapies. During rAAV production, only a fraction of AAV capsids package the desired gene of interest properly, and the unwanted empty AAV byproducts reduce the therapy’s success. To manufacture pure recombinant viral vectors, researchers implement stringent quality control measures at every step of the production process.
Download this application note from Bio-Techne to learn about Simple Western™, an instrument that combines capillary electrophoresis and immunodetection to distinguish between empty and fully-assembled particles, offering high sensitivity, reproducibility, and scalability in rAAV manufacturing.
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.